IACR Newsflash

Haematological Malignancies in Belgium, 2004-2018

Our colleagues at the Belgian Cancer Registry (BCR) are pleased to share their new E-book publication, Haematological Malignancies - Belgium 2004-2018.

This publication is the result of close collaboration between the BCR and the Belgian Hematology Society (BHS) and of a partnership with the Belgian Society of Paediatric Haematology Oncology (BSPHO).

This e-book describes the epidemiological situation of haematological malignancies in Belgium for 15 consecutive years of incidence data. In addition to results on incidence, prevalence, 5-year survival and trends as presented in the last publication on haematological malignancies in 2015, this new publication will also include incidence projections until 2025 and 10-year relative survival for the main haematological subtypes.

The E-book can be downloaded through this link: 

The e-book is available through the link here: HM 20014-2018 E-Book 

or through the BCR's Publications page. 


IACR congratulates our colleagues at the Belgian Cancer Registry and the clinical societies they worked with to produce this impressive report.




Enrico Anglesio 2021 Virtual Prize Open

We are again calling our young colleagues and researchers working in cancer registration and epidemiology to present your work at this year's IACR 2021 Virtual Conference and be eligible for the Enrico Anglesio Awards for 2021Applications are now being accepted:

The Enrico Anglesio Prize is awarded every year to a young cancer epidemiology researcher who has prepared an original work in the domain of epidemiology, cancer registration. From 2006 to 2020, over 160 young researchers contested, and 25 have been declared Enrico Anglesio Laureates. In 2020, with the cancellation of the in-person scientific conferences where the Prize was awarded, the Fondo Elena Moroni kept the prize going with the virtual awards. Two satellite awards, the Elvo Tempia and the Sharon Whelan, respectively offered by the Tempia Foundation and the IACR, accompanied the Enrico Anglesio main Prize. The Elvo Tempia Special Prize, offered by the Fondazione Tempia, in Biella, Italy goes to the youngest, best-scoring candidate following the EAP main prize winner.  The Sharon S Whelan Special Prize, offered by the International Association of Cancer registries, goes to the best-scoring candidate coming from a Low-Middle Income country.

For 2021, the annual meeting of the IACR will be held virtually the 12th-14th October and the Fondo Elena Moroni is organising the Enrico Anglesio awards in the same virtual format as last year.  The contest will open on 1st July 2021. From that day on, it will be possible to submit the application via the website, clicking the correspondent button.  The deadline for submitting the Application Form and the Written Dissertation (step 1) will be the 20th of August. 

The candidate must be first or only author on the submitted paper, that has not been previously published.

The 2020 awardees were:

  • Diana R Withrow, National Cancer Institute, Bethesda, USA (Enrico Anglesio Main Prize)
  • Christiane Rudolph, University of Lubeck, Germany (Elvo Tempia Prize); and
  • Wilmer A Tarupi, UTE University, Quito, Ecuador (IACR Sharon Whelan Prize)


Cancer registry news on Twitter

For those on Twitter:  follow GICR @ IARC for the latest on cancer registration, cancer data and cancer control activities and updates around the world.

For our cancer registry members and colleagues: contact us if you would like us to share your publications, research and activities on this website, our mailing list and on twitter.


Updates on ICD-O 3.2 and ICD-O 4

ICD-O-4 (Update as of January 25, 2021)

With the new 5th edition of the Blue Books commencing (it will be completed by mid-2023), it is now the time for the IARC WHO Classification of Tumours Group to start creating new codes. Due to the lack of available codes for new morphological diagnoses in the current 4-digit morphology structure, it is proposed for the next ICD-O edition (ICD-O-4) that a 5th digit will be added.

This approach, with the addition of a “0” where there is no need for a more specific code, or other values if needed was chosen for the ease of conversion and consistency with ICD-O-3 (similar to a MOTNAC to ICD-O-1 conversion). Adding an additional digit to the existing four retains the needed consistency, including the possibility to collapse to previous versions, but will likely require minor changes in registry software, notification forms, etc.

As the previous IACR ICD-O Working Group has now concluded its work with ICD-O-3.2, IACR will establish a new WG with global representation, with a terms of reference that focuses on the required planning for the implementation of ICD-O-4 in cancer registries worldwide.


ICD-O-3.2 (Update as of January 25, 2021):


The preparation of ICD-O-3.2 book (pdf) is at its final stages at the WHO Press, and we hope to have it in the first half of 2021. In the meantime, please refer to the tables available in this page.

Please read through our page on the International Classification of Diseases for Oncology (ICD-O) for details and updates of ICD-O-3.2 and the work that will start for ICD-O-4:

Support for Registries / ICD-O

Dr Risto Sankila (1958 – 2019)

Dr Risto Sankila was a former Director of the Finnish Cancer Registry, and led the organization of the IACR 2002 scientific conference in Helsinki (June 2002). He also served as Professor at the Tampere University until 2008. 

As Dr Sankila mastered the subject of survival analysis, he went to IARC in Lyon and substantially contributed to the work of the European Network of Cancer Registries. He served as editor of the IARC Technical Publications No. 37: Evaluation of Clinical Care by Cancer Registries (2003).

Read the full tribute by Dr Roberto Zanetti and Jan Willem Coebergh here: https://www.fondoelenamoroni.org/category/notizie/

  •  Start 
  •  Prev 
  •  1  2  3  4 
  •  Next 
  •  End 

Page 1 of 4

Our partners

120507 01b LOGO X3





This website was developed and is hosted at the International Agency for Research on Cancer (IARC)
Go to top